Arbutus Biopharma
ABUS
63 hedge funds and large institutions have $442M invested in Arbutus Biopharma in 2015 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 31 increasing their positions, 10 reducing their positions, and 23 closing their positions.
210% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 10
38% more call options, than puts
Call options by funds: $4.05M | Put options by funds: $2.95M
18% less funds holding
Funds holding: 77 → 63 (-14)
28% less capital invested
Capital invested by funds: $616M → $442M (-$173M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
57% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 23
Top Buyers
| 1 |
Primecap Management
Pasadena,
California
|
+$23.3M |
| 2 |
HM
HealthCor Management
New York
|
+$15.3M |
| 3 |
Millennium Management
New York
|
+$15M |
| 4 |
AWG
Alpha Wave Global
New York
|
+$6.04M |
| 5 |
RIM
RS Investment Management
San Francisco,
California
|
+$6.03M |
Top Sellers
ABUS Hedge Fund Activity: Q2 2015 in Review
63 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q2 2015, worth a combined $442M — down 28% from $616M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of ABUS and 10 opened new positions — a net loss of 13 holders — while 10 trimmed existing stakes and 31 added.
The largest buyer was Primecap Management, adding an estimated $23.3M. The largest seller was RA Capital Management, exiting entirely with an estimated $47.4M sold.
- 63 institutional investors held Arbutus Biopharma (ABUS) as of Q2 2015, down from 77 in Q1 2015.
- Funds reported $442M of Arbutus Biopharma stock for Q2 2015, down 28% quarter-over-quarter.
- 10 funds opened new Arbutus Biopharma positions in Q2 2015 and 23 closed out, a net change of -13 holders.
- The largest Arbutus Biopharma buyer in Q2 2015 was Primecap Management, an estimated $23.3M added.
- The largest Arbutus Biopharma seller in Q2 2015 was RA Capital Management, an estimated $47.4M sold.
Based on aggregated 13F filings for Q2 2015.